Format

Send to

Choose Destination
Vaccine. 2016 Feb 3;34(6):831-8. doi: 10.1016/j.vaccine.2015.12.009. Epub 2015 Dec 17.

A field vaccine trial in Tanzania demonstrates partial protection against malignant catarrhal fever in cattle.

Author information

1
Boyd Orr Centre for Population and Ecosystem Health, Institute of Biodiversity, Animal Health & Comparative Medicine, University of Glasgow, Glasgow, G12 8QQ, UK; Paul G. Allen School for Global Animal Health, Washington State University, Pullman, WA 99164, USA; School of Life Sciences and Bioengineering, Nelson Mandela African Institution of Science & Technology, Arusha, Tanzania. Electronic address: lankesterf@vetmed.wsu.edu.
2
Moredun Research Institute, Midlothian, Edinburgh, UK.
3
Faculty of Veterinary Medicine, Sokoine University of Agriculture, Morogoro, Tanzania.
4
School of Life Sciences and Bioengineering, Nelson Mandela African Institution of Science & Technology, Arusha, Tanzania; Department of Science and Laboratory Technology, Dar es Salaam Institute of Technology, Dar es Salaam, Tanzania.
5
School of Life Sciences and Bioengineering, Nelson Mandela African Institution of Science & Technology, Arusha, Tanzania.
6
Tanzanian Wildlife Research Institute, Arusha, Tanzania.
7
School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK.
8
Boyd Orr Centre for Population and Ecosystem Health, Institute of Biodiversity, Animal Health & Comparative Medicine, University of Glasgow, Glasgow, G12 8QQ, UK; School of Life Sciences and Bioengineering, Nelson Mandela African Institution of Science & Technology, Arusha, Tanzania.

Abstract

Malignant catarrhal fever (MCF) is a fatal lymphoproliferative disease of cattle that, in East Africa, results from transmission of the causative virus, alcelaphine herpesvirus 1 (AlHV-1), from wildebeest. A vaccine field trial involving an attenuated AlHV-1 virus vaccine was performed over two wildebeest calving seasons on the Simanjiro Plain of northern Tanzania. Each of the two phases of the field trial consisted of groups of 50 vaccinated and unvaccinated cattle, which were subsequently exposed to AlHV-1 challenge by herding toward wildebeest. Vaccination resulted in the induction of virus-specific and virus-neutralizing antibodies. Some cattle in the unvaccinated groups also developed virus-specific antibody responses but only after the start of the challenge phase of the trial. PCR of DNA from blood samples detected AlHV-1 infection in both groups of cattle but the frequency of infection was significantly lower in the vaccinated groups. Some infected animals showed clinical signs suggestive of MCF but few animals went on to develop fatal MCF, with similar numbers in vaccinated and unvaccinated groups. This study demonstrated a baseline level of MCF-seropositivity among cattle in northern Tanzania of 1% and showed that AlHV-1 virus-neutralizing antibodies could be induced in Tanzanian zebu shorthorn cross cattle by our attenuated vaccine, a correlate of protection in previous experimental trials. The vaccine reduced infection rates by 56% in cattle exposed to wildebeest but protection from fatal MCF could not be determined due to the low number of fatal cases.

KEYWORDS:

Alcelaphine herpesvirus 1; Malignant catarrhal fever; Tanzania; Vaccine efficacy; Vaccine field trial; Wildebeest

PMID:
26706270
PMCID:
PMC4742522
DOI:
10.1016/j.vaccine.2015.12.009
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center